Allergen immunotherapy: does it work and, if so, how and for how long?

This publication has 23 references indexed in Scilit:

• Nasal immunotherapy - not to be sneezed at
  Clinical and Experimental Allergy, 1998
• Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?
  Clinical and Experimental Allergy, 1998
• Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy
  Nature Biotechnology, 1997
• Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.
  Journal of Clinical Investigation, 1997
• Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals.
  The Journal of Experimental Medicine, 1993
• Detection of crossreactive determinants in grass pollen extracts using monoclonal antibodies against group IV and group V allergens
  Clinical and Experimental Allergy, 1993
• Predominant T_H2-like Bronchoalveolar T-Lymphocyte Population in Atopic Asthma
  New England Journal of Medicine, 1992
• Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs.
  BMJ, 1991
• Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis
  Clinical and Experimental Allergy, 1991
• The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST
  Clinical and Experimental Allergy, 1978